share_log

誉衡药业(002437.SZ):下半年公司核心产品的集采压力不大

Harbin Gloria Pharmaceuticals (002437.SZ): There is not much pressure on the centralized procurement of the company's core products in the second half of the year.

Gelonghui Finance ·  Jul 8 19:30

On July 9th, Gelunhui reported that Harbin Gloria Pharmaceuticals (002437.SZ) stated during a recent investor visit to institutions that the company's main products, including Deer Antler Polypeptide Injection, Potassium Chloride Sustained-Release Tablets (Budexiu), and various vitamins (12) for injection, have already been included in centralized procurement. An Nao Wan/Pian does not yet meet the conditions for centralized procurement. In the second half of the year, the company's core products face little pressure from centralized procurement.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment